REPLAY Trial
Cross-source consensus on REPLAY Trial from 1 sources and 7 claims.
1 sources · 7 claims
Other
Other
Other
Other
Highlighted claims
- The untreated cohort is a multicentre, double-masked, placebo-controlled parallel-group trial targeting 60 patients randomised 2:1 to rf-PDT or placebo. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
- The REPLAY trial is a phase III investigator-initiated pivotal study. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
- The previously treated cohort is an exploratory single-arm open-label study of up to 10 patients with recurrent CSC after prior PDT. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
- The REPLAY trial aims to obtain regulatory approval and national health insurance reimbursement in Japan. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
- Both REPLAY cohorts share a 48-week follow-up protocol. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
- Recruitment began in January 2024 and estimated study completion is December 2026. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
- Four tertiary ophthalmology centres participate in the REPLAY trial. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial